Jason Laine

Alabama’s Marijuana Rescheduling Standoff: What’s Really at Stake 0
- MEDICAL MARIJUANA
- August 4, 2026
Alabama has triggered a state review process over federal marijuana rescheduling, but legal experts say headlines calling it an “opt-out” miss the mark. When the DEA reclassified medical marijuana to Schedule 3 in April, Alabama law required automatic adoption—unless the State Committee of Public Health objected within 30 days. It did, prompting a review that
READ MORE
THC/CBD Trial Eases End-of-Life Agitation in Dementia 0
- CANNABIS OIL
- July 28, 2026
A phase 2 clinical trial has found that a THC/CBD combination significantly reduced agitation in hospice-eligible people with dementia, with benefits appearing within two weeks and lasting through 12 weeks. The study, known as LiBBY, enrolled 120 participants and met both its primary and key secondary endpoints, according to results reported at the Alzheimer’s Association
READ MORE

Employers Reassess Cannabis Testing 0
- MEDICAL MARIJUANA
- July 22, 2026
Employers are rethinking cannabis testing as legalization expands, positive drug test rates rise, and workplace policies face new legal pressure. A recent JD Supra report says federal rescheduling of certain medical cannabis products could increase accommodation requests and ADA disputes, especially in states without strong employment protections. The article, “Cannabis Laws Are Changing: 8 Questions
READ MORE
Cannabis Treatment Shows Promise for Easing Dementia Agitation 0
- CANNABIS OIL
- July 14, 2026
A small clinical trial presented this week suggests that a carefully dosed combination of THC and CBD may significantly ease agitation in people with advanced dementia. In the 12‑week study of 120 hospice-eligible patients, nearly 90 percent of those receiving the cannabinoid treatment saw agitation decrease, compared with less than a quarter in the placebo
READ MORE